Onconetix Inc Total Liabilities
Onconetix Inc total liabilities. Based on the latest financial reports, Onconetix Inc (ONCO) has total liabilities worth $3.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Onconetix Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Onconetix Inc (2019–2025)
Total liabilities of Onconetix Inc from 2019 to 2025. This chart illustrates how Onconetix Inc's total liabilities have evolved over time, based on quarterly financial data.
Onconetix Inc Competitors by Total Liabilities
The table below lists competitors of Onconetix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
Germany | €185.77K |
|
GlucoTrack Inc
NASDAQ:GCTK
|
USA | $3.24 Million |
|
Mongolia Growth Group Ltd.
V:YAK-H
|
Canada | CA$304.26K |
|
GROUNDED PEOPLE APPAREL
F:K1G
|
Germany | €885.34K |
|
LED iBond International AS
CO:LEDIBOND
|
Denmark | Dkr22.90 Million |
|
Asdion Bhd
KLSE:0068
|
Malaysia | RM18.03 Million |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
Germany | €34.88 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Onconetix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ONCO asset base.
Liquidity & Leverage Metrics
Onconetix Inc Total Liabilities Ratios Explained
Onconetix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Onconetix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Onconetix Inc (2019–2025)
The table below shows the annual total liabilities of Onconetix Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.16 Million | -50.67% |
| 2024-12-31 | $18.57 Million | -78.43% |
| 2023-12-31 | $86.11 Million | +2095.41% |
| 2022-12-31 | $3.92 Million | +139.45% |
| 2021-12-31 | $1.64 Million | +1991.84% |
| 2020-12-31 | $78.31K | -5.22% |
| 2019-12-31 | $82.62K | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more